Raffaele Colombo: Phase 1b of BL-B01D1 in Esophageal Squamous Cell Carcinoma
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks Inc., shared a post on X about a recent paper by Chang Liu et al. published in Nature Medicine:
“Phase 1b of BL-B01D1 (EGFRxHER3 TOPO1i BsADC) in esophageal squamous cell carcinoma published in Nature Medicine.
2.5 mg/kg D1D8 Q3W, ORR=40% (21/53)
2.0 mg/kg D1D8 Q3W, ORR=15% (3/20)
No significant correlation between response and expression of EGFR, HER3, or both (small number of patients).”
Title: A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial
Journal: Nature Medicine
Authors: Chang Liu, Dan Liu, Yinghua Ji, Meili Sun, Shegan Gao, Xuelei Ma, Diansheng Zhong, Ji Zhu, Yanshuo Cao, Changsong Qi, Miao Zhang, Panpan Zhang, Ran Xue, Zhi Peng, Jun Zhou, Sai Ge, Ming Lu, Jiajia Yuan, Yakun Wang, Zhenghang Wang, Jian Li, Xiaotian Zhang, Yi Zhu, Hai Zhu, Sa Xiao, Jifang Gong, Lin Shen, Zhihao Lu
More posts featuring Raffaele Colombo on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023